Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.805 USD | -2.96% | +17.21% | +42.13% |
03:20pm | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
16/05 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.13% | 12.05M | |
+39.87% | 54.04B | |
+44.70% | 41.96B | |
-1.51% | 41.92B | |
-7.20% | 28.35B | |
+12.44% | 26.35B | |
-21.73% | 19B | |
+6.97% | 13B | |
+29.06% | 12.28B | |
+25.69% | 12.19B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501